facts and figures 2007

Download
Share  Add to  Flag Embed
Uploaded from authorPOINTLite
Views:
 
Category: Education
     
 
License:   All Rights Reserved

Presentation Description

No description available.

Comments

Presentation Transcript

Slide1: 

ﴀ ﴀ 1.01 The number of active substances with a Norwegian marketing authorisation

Slide2: 

1.02 New and withdrawn active ingredients

Slide3: 

1.03 Number of medicines in Norway

Slide4: 

1.04 The number of marketing authorisations in Norway

Slide5: 

1.05 Pharmaceutical sales in Norway in the last few years, 2006-currency

Slide6: 

1.06 Pharmaceutical sales in Norway historically

Slide7: 

1.07 Percentual annual growth in medicine sales

Slide8: 

1.08 Pharmaceutical sales per inhabitant in Norway the last few years

Slide9: 

1.09 Pharmaceutical sales per inhabitant historically

Slide10: 

1.10 Sales growth by volume

Slide11: 

1.11 The Norwegian pharmaceutical market by main therapeutic groups (ATC)

Slide12: 

1.12 The top 25 pharmaceutical companies on the Norwegian market

Slide13: 

1.13 The top 25 medicines on the Norwegian market in terms of sales value

Slide14: 

1.14 The 25 most sold medicines in terms of defined daily doses (DDD)

Slide15: 

1.15 The top 25 active ingredients in terms of sales value

Slide16: 

1.16 The top 25 active ingredients as measured by defined daily doses (DDD)

Slide17: 

1.17 Total sales by distribution chain

Slide18: 

1.18 New innovative medicines´ share of total medicine sales

Slide19: 

1.19 Sales of new innovative medicines by medicine group

Slide20: 

1.20 Sales of generics, DDD

Slide21: 

1.21 Generics´ share of the generics interchangeable market

Slide22: 

1.22 Sales of parallel imported medicines

Slide23: 

ﴀ ﴀ 1.23 Market share for Wholesalers

Slide24: 

1.24 Pharmacy chain affiliation

Slide25: 

1.25 Pharmacy chain market share

Slide26: 

1.26 Pharmacy chain market share, excl. hospital pharmacies

Slide27: 

2.01 Changes in medicine prices and the general rate of inflation

Slide28: 

2.02 Public spending on reimbursable prescription medicines

Slide29: 

2.03 Payment for pharmaceutical consumption

Slide30: 

2.04 Public spending on medicines per inhabitant

Slide31: 

2.06 Public spending on health care and medicines

Slide32: 

2.07 Public spending on medicines as a percentage of public health expenditure

Slide33: 

2.08 Expenditure on medicines in the private and public sector

Slide34: 

2.09 Daily costs for consumption of medicines

Slide35: 

ﴀ ﴀ 2.11 Pharmaceutical expenditure as share of the total expenditure in healthcare institutions in Norway

Slide36: 

2.12 National Insurance expenditure

Slide37: 

2.13 Expenditure on health care

Slide38: 

3.01 Non-prescription medicines, share of total market value (PRP)

Slide39: 

3.02 Non-prescription medicines, share of total market (DDD)

Slide40: 

3.03 The top 25 non-prescription medicines in terms of sales value

Slide41: 

3.04 Non-prescription medicines sales by selected therapy groups (ATC)

Slide42: 

3.05 The top 10 pharmaceutical companies in the non-prescription medicines market

Slide43: 

3.06 The top 10 pharmaceutical companies in terms of OTC share of total sales0

Slide44: 

ﴀ ﴀ 3.07 Sales of non-prescription medicines

Slide45: 

3.08 Sales of non-prescription medicines DDDs

Slide46: 

3.09 Non-prescription medicines, market share (PRP) in selected countries

Slide47: 

3.10 Number of general sales outlets for non-prescription medicines outside pharmacies by trade

Slide48: 

3.11 OTC market shares (DDD) – Pharmacies vs general sales outlets

Slide49: 

4.01 The top 10 veterinary medicines for aquaculture in terms of sales value

Slide50: 

4.02 The top 10 veterinary medicines for mammals in terms of sales value

Slide51: 

ﴀ ﴀ 4.03 The top 5 companies within aquaculture

Slide52: 

4.04 The top 10 companies within veterinary medicine excluding aquaculture

Slide53: 

4.05 Sales veterinary antibacterial medicinal products

Slide54: 

4.06 Fish farming and use of antibiotics

Slide55: 

4.07 Distribution of sales in the market for medicines for mammals

Slide56: 

5.01 The pharmaceutical industry's investments in research and development

Slide57: 

5.02 Investments in R&D, percentage of sales

Slide58: 

5.03 Submitted clinical trials

Slide59: 

5.04 Number of ongoing clinical trials within the pharmaceutical industry

Slide60: 

5.05 Number of patients in clinical studies

Slide61: 

ﴀ ﴀ 5.06 Industry initiated clinical trials

Slide62: 

5.07 Norway's imports and exports of medicines

Slide63: 

5.08 Number of countries receiving pharmaceuticals produced in Norway

Slide64: 

5.09 Number of employees in the pharmaceutical industry in Norway

Slide65: 

5.10 Employees in pharmaceutical companies with production plants in Norway

Slide66: 

6.01 International price index for medicines

Slide67: 

6.02 Leading pharmaceutical companies on the global market

Slide68: 

6.03 Mergers and acquisitions

Slide69: 

6.04 Leading pharmaceuticals on the global market

Slide70: 

6.05 The Norwegian medicines market in relation to Europe

Slide71: 

6.06 Pharmaceutical consumption (DDD) in the Nordic countries pr inhabitant

Slide72: 

6.07 Medicines sales (PPP) per inhabitant in the Nordic Countries

Slide73: 

6.08 Sales evolution for medicines in the Nordic Countries

Slide74: 

6.09 Spending on health care and pharmaceuticals in the OECD

Slide75: 

6.10 Spending on medicines as share of spending on health care in the OECD

Slide76: 

6.11 Public spending on medicines as a percentage of public health care expenditure in the OECD

Slide77: 

6.12 Raesearch and development costs for new medicines

Slide78: 

6.13 Percentage of medicines stopped at each stage of development

Slide79: 

6.14 Total number of new active substances introduced worldwide

Slide80: 

6.15 The pharmaceutical industry's investments in research and development in Europe

Slide81: 

6.16 Total R&D investements divided into biotech and other medicines

Slide82: 

6.17 The pharmaceutical industry's R&D investments in Europa and the U.S

Slide83: 

6.18 Allocation of R&D investments by category

Slide84: 

6.19 R&D expenses biotechnology divided by region

Slide85: 

6.20 Distribution of global pharmaceutical sales by region

Slide86: 

6.21 Global sales growth medicines

Slide87: 

6.22 Pharmaceutical expenditure as share of health expenditure in Europe

Slide88: 

6.23 Copayment for reimbursable medicines

Slide89: 

6.24 VAT on medicines and other goods and services in Europe

Slide90: 

6.25 Generics share of total market

Slide91: 

6.26 Number of inhabitants per pharmacy in Europe

Slide92: 

6.27 Distribution of medicine sales in the Nordic countries

Slide93: 

6.28 R&D investments as a percentage of Gross Domestic Product

Slide94: 

7.01 Medicine sales by county

Slide95: 

7.02 Inhabitants per physician in the counties

Slide96: 

7.03 Finnmark

Slide97: 

7.04 Troms

Slide98: 

7.05 Nordland

Slide99: 

7.06 Nord-Trøndelag

Slide100: 

7.07 Sør-Trøndelag

Slide101: 

7.08 Møre og Romsdal

Slide102: 

7.09 Sogn og Fjordane

Slide103: 

7.10 Hordaland

Slide104: 

7.11 Rogaland

Slide105: 

7.13 Aust-Agder

Slide106: 

7.14 Telemark

Slide107: 

7.15 Vestfold

Slide108: 

7.16 Buskerud

Slide109: 

7.17 Akershus

Slide110: 

7.18 Oslo

Slide111: 

7.19 Oppland

Slide112: 

7.20 Hedmark

Slide113: 

7.21 Østfold